Patient dosing commenced in reposa phase 2/3 clinical trial protocol to assess ihl-42x drug in patients with obstructive sleep apnea

New york and melbourne, australia, may 30, 2024 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl), (‘incannex' or the ‘company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the company's phase 2/3 clinical trial to assess safety and efficacy of ihl-42x in patients with obstructive sleep apnea (‘osa').
IXHL Ratings Summary
Quant
IXHL Quant Ranking
Sector
Industry
Quant Rating
Quant Score